The COVID-19 pandemic has presented several operational challenges for the pharmaceutical and healthcare industry.

GlobalData had conducted a survey to identify how the COVID-19 pandemic affected clinical trial planning for clinical trial sponsors, collaborators or contract research organisations (CROs).

An analysis of the survey reveals that 30% of the respondents believe that the pandemic would impact patient recruitment, while 17% of the companies felt that investigator recruitment would be affected. ​

Clinical trial planning

Impact of COVID-19 Social Distancing Measures on Clinical Trials

Another 17% of the respondents highlighted that the pandemic will disrupt the supply of clinical trial materials due to restrictions and lockdowns measures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, 14% of the respondents are planning to either cancel or postpone trials, while another 10% opnied that regulator resources are stretched amid the pandemic.

Around 5% of the surveyed companies are mulling to change the location of the trial, while 4% noted that they have no clinical trials planned in the next two years.

Only 4% of the respondents said that the COVID-19 pandemic will not affect their trial programmes.

The analysis is based on responses received from the GlobalData Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain, 2020 conducted between 13 March and 24 March 2020.